CELU实时信号 | 通过Getagraph.com最大化利润

购买 110120 min ago

@ $0.410

发出时间: 13 Feb 2024 @ 05:00

回报率: 636.59%

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
今日成交量	48 969.00
平均成交量	96 312.00
市值	65.78M
EPS	$0 ( 2024-04-02 )
下一个收益日期	( $-0.140 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.290
ATR14	$0.0260 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-13	Fletcher Kyle	Sell	20	Class A Common Stock
2024-04-13	Haines John R	Sell	576	Class A Common Stock
2024-04-13	Beers David C	Sell	360	Class A Common Stock
2024-04-13	Hariri Robert J	Sell	1 154	Class A Common Stock
2024-04-13	Brigido Stephen	Sell	268	Class A Common Stock

INSIDER POWER
57.07
Last 98 transactions
Buy: 89 262 897 \| Sell: 26 354 903

音量相关性

長: -0.01 (neutral)

短: -0.26 (neutral)

Signal:(49.54) Neutral

Celularity Inc. 相关性

10 最正相关
ASPS	0.945
AUID	0.931
CLFD	0.93
PROG	0.93
OP	0.927
AYLA	0.927
JUPW	0.925
PCSA	0.925
ADP	0.925
DWACU	0.923

10 最负相关
CBAY	-0.935
TIOA	-0.926
CITE	-0.922
FXCO	-0.917
BWC	-0.915
XPDB	-0.915
BRIV	-0.914
TIOAU	-0.914
ROCL	-0.914
ITAQ	-0.912

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Celularity Inc. 相关性 - 货币/商品

0.46
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.31
( neutral )

0.15
( neutral )

-0.61
( weak negative )

Celularity Inc. 财务报表

Annual	2022
营收:	$17.98M
毛利润:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
营收:	$17.98M
毛利润:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
营收:	$21.34M
毛利润:	$17.69M (82.90 %)
EPS:	$-12.49

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0215

Financial Reports:

No articles found.

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.